Patents by Inventor Chichi Huang

Chichi Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MATERIALS AND METHODS FOR IMPROVED SINGLE CHAIN VARIABLE FRAGMENTS
    Publication number: 20240067754
    Abstract: Disclosed are materials and methods for improved single chain variable fragments.
    Type: Application
    Filed: September 5, 2023
    Publication date: February 29, 2024
    Inventors: Jinquan LUO, Lauren BOUCHER, Michael FELDKAMP, Michael DIEM, Anthony A. ARMSTRONG, Alexey TEPLYAKOV, Chichi HUANG
  • Materials and methods for improved single chain variable fragments
    Patent number: 11787875
    Abstract: Disclosed are materials and methods for improved single chain variable fragments.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: October 17, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Jinquan Luo, Lauren Boucher, Michael Feldkamp, Michael Diem, Anthony A. Armstrong, Alexey Teplyakov, Chichi Huang
  • GLUCAGON LIKE PEPTIDE 1 (GLP1)-GROWTH DIFFERENTIATION FACTOR 15 (GDF15) FUSION PROTEINS AND USES THEREOF
    Publication number: 20230322888
    Abstract: Provided herein are GLP1-GDF15 fusion proteins comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.
    Type: Application
    Filed: June 9, 2023
    Publication date: October 12, 2023
    Inventors: Shannon MULLICAN, Matthew M. RANKIN, Xiefan LIN-SCHMIDT, Chichi HUANG, Jennifer FURMAN, Songmao ZHENG, Shamina RANGWALA, Serena NELSON
  • ANTI-CD3 ANTIBODIES AND USES THEREOF
    Publication number: 20230322924
    Abstract: The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.
    Type: Application
    Filed: March 8, 2023
    Publication date: October 12, 2023
    Inventors: Francois Gaudet, Jill Giles-Komar, Bradley Heidrich, Chichi Huang, Colleen Kane, Ronan Mcdaid, Jennifer Nemeth-Seay
  • Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof
    Patent number: 11713345
    Abstract: Provided herein are GLP1-GDF15 fusion proteins comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: August 1, 2023
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Shannon Mullican, Matthew M. Rankin, Xiefan Lin-Schmidt, Chichi Huang, Jennifer Furman, Songmao Zheng, Shamina Rangwala, Serena Nelson
  • GDF15 FUSION PROTEINS AND USES THEREOF
    Publication number: 20230119382
    Abstract: Fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein are described. Also described are nucleic acids encoding the fusion proteins, recombinant cells thereof, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing metabolic diseases, disorders or conditions.
    Type: Application
    Filed: November 18, 2021
    Publication date: April 20, 2023
    Inventors: Anthony ARMSTRONG, Judith Ann CONNOR, Jennifer FURMAN, Chichi HUANG, Michael J. HUNTER, Xiefan LIN-SCHMIDT, Serena NELSON, Shamina M. RANGWALA, Shannon MULLICAN, Jose Antonio CHAVEZ
  • Anti-CD3 antibodies and uses thereof
    Patent number: 11603405
    Abstract: The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The present invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: March 14, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Francois Gaudet, Jill Giles-Komar, Bradley Heidrich, Chichi Huang, Colleen Kane, Ronan McDaid, Jennifer Nemeth-Seay
  • Antibodies to Pyroglutamate Amyloid-B and Uses Thereof
    Publication number: 20220177560
    Abstract: The invention provides antibodies or antigen binding fragments thereof that bind to 3pE A? and methods of making and using the antibodies or antigen binding fragments thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other ?-amyloid-related diseases.
    Type: Application
    Filed: March 25, 2020
    Publication date: June 9, 2022
    Inventors: Bianca Van Broeck, Marc Mercken, Wilson Edwards, Sanjaya Singh, Jinquan Luo, Sherry La Porte, Rajkumar Ganesan, Chichi Huang
  • Antigen Binding Regions Against Fibronectin Type III Domains and Methods of Using the Same
    Publication number: 20220127343
    Abstract: Fibronectin type III (FN3) domain antibodies, polynucleotides capable of encoding the FN3 domain antibodies or antigen-binding fragments, cells expressing FN3 domain antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled FN3 domain antibodies or antigen-binding fragments may be used to engineer FN3 domain-targeting chimeric antigen receptors (CARs). Methods of making the FN3 domain antibodies, CARs, and engineered immune cells, and methods of using the engineered immune cells are applicable to treat diseases including cancer.
    Type: Application
    Filed: October 4, 2021
    Publication date: April 28, 2022
    Inventors: Chichi Huang, John Lee, Jill Mooney, Michael Naso
  • ANTIBODIES TO PYROGLUTAMATE AMYLOID-B AND USES THEREOF
    Publication number: 20220106387
    Abstract: The invention provides antibodies or antigen binding fragments thereof that bind to 3pE A? and methods of making and using the antibodies or antigen binding fragments thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other ?-amyloid-related diseases.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 7, 2022
    Inventors: Bianca Van Broeck, Marc Mercken, Wilson Edwards, Sanjaya Singh, Jinquan Luo, Sherry La Porte, Rajkumar Ganesan, Chichi Huang
  • GLUCAGON LIKE PEPTIDE 1 (GLP1)-GROWTH DIFFERENTIATION FACTOR 15 (GDF15) FUSION PROTEINS AND USES THEREOF
    Publication number: 20220089669
    Abstract: Provided herein are GLP1-GDF15 fusion proteins comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.
    Type: Application
    Filed: October 22, 2019
    Publication date: March 24, 2022
    Inventors: Shannon MULLICAN, Matthew M. RANKIN, Xiefan LIN-SCHMIDT, Chichi HUANG, Jennifer FURMAN, Songmao ZHENG, Shamina RANGWALA, Serena NELSON
  • Antibodies to pyroglutamate amyloid-? and uses thereof
    Patent number: 11236155
    Abstract: The invention provides antibodies or antigen binding fragments thereof that bind to 3pE A? and methods of making and using the antibodies or antigen binding fragments thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other ?-amyloid-related diseases.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: February 1, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bianca Van Broeck, Marc Mercken, Wilson Edwards, Sanjaya Singh, Jinquan Luo, Sherry La Porte, Rajkumar Ganesan, Chichi Huang
  • GDF15 fusion proteins and uses thereof
    Patent number: 11208464
    Abstract: Fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein are described. Also described are nucleic acids encoding the fusion proteins, recombinant cells thereof, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing metabolic diseases, disorders or conditions.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: December 28, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Anthony Armstrong, Judith Ann Connor, Jennifer Furman, Chichi Huang, Michael J. Hunter, Xiefan Lin-Schmidt, Serena Nelson, Shamina M. Rangwala, Shannon Mullican, Jose Antonio Chavez
  • Antigen binding regions against fibronectin type III domains and methods of using the same
    Patent number: 11161897
    Abstract: Fibronectin type III (FN3) domain antibodies, polynucleotides capable of encoding the FN3 domain antibodies or antigen-binding fragments, cells expressing FN3 domain antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled FN3 domain antibodies or antigen-binding fragments may be used to engineer FN3 domain-targeting chimeric antigen receptors (CARs). Methods of making the FN3 domain antibodies, CARs, and engineered immune cells, and methods of using the engineered immune cells are applicable to treat diseases including cancer.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: November 2, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Chichi Huang, John Lee, Jill Mooney, Michael Naso
  • MATERIALS AND METHODS FOR IMPROVED SINGLE CHAIN VARIABLE FRAGMENTS
    Publication number: 20210047435
    Abstract: Disclosed are materials and methods for improved single chain variable fragments.
    Type: Application
    Filed: August 14, 2020
    Publication date: February 18, 2021
    Inventors: Jinquan Luo, Lauren Boucher, Michael Feldkamp, Michael Diem, Anthony A. Armstrong, Alexey Teplyakov, Chichi Huang
  • Antibodies to Pyroglutamate Amyloid-B and Uses Thereof
    Publication number: 20200308261
    Abstract: The invention provides antibodies or antigen binding fragments thereof that bind to 3pE A? and methods of making and using the antibodies or antigen binding fragments thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other ?-amyloid-related diseases.
    Type: Application
    Filed: March 25, 2020
    Publication date: October 1, 2020
    Inventors: Bianca Van Broeck, Marc Mercken, Wilson Edwards, Sanjaya Singh, Jinquan Luo, Sherry La Porte, Rajkumar Ganesan, Chichi Huang
  • Interferon alpha and omega antibody antagonists
    Patent number: 10759854
    Abstract: The present invention relates to antibodies that broady neutralize interferon-? and interferon-?, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: September 1, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Ellen Chi, Judith Connor, Chichi Huang, Jarrat Jordan, Xiefan Lin-Schmidt, Jinquan Luo, Lu Lu, Christian Martinez, Galina Obmolova, Ronald Swanson
  • ANTI-CD3 ANTIBODIES AND USES THEREOF
    Publication number: 20200048349
    Abstract: The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The present invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.
    Type: Application
    Filed: May 21, 2019
    Publication date: February 13, 2020
    Inventors: Francois GAUDET, Jill GILES-KOMAR, Bradley HEIDRICH, Chichi HUANG, Colleen KANE, Ronan MCDAID, Jennifer NEMETH-SEAY
  • Interferon Alpha and Omega Antibody Antagonists
    Publication number: 20190359705
    Abstract: The present invention relates to antibodies that broady neutralize interferon-? and interferon-?, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: May 29, 2019
    Publication date: November 28, 2019
    Inventors: Ellen Chi, Judith Connor, Chichi Huang, Jarrat Jordan, Xiefan Lin-Schmidt, Jinquan Luo, Lu Lu, Christian Martinez, Galina Obmolova, Ronald Swanson
  • GDF15 FUSION PROTEINS AND USES THEREOF
    Publication number: 20190292241
    Abstract: Fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein are described. Also described are nucleic acids encoding the fusion proteins, recombinant cells thereof, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing metabolic diseases, disorders or conditions.
    Type: Application
    Filed: May 15, 2019
    Publication date: September 26, 2019
    Inventors: Anthony Armstrong, Judith Ann Connor, Jennifer Furman, Chichi Huang, Michael J. Hunter, Xiefan Lin-Schmidt, Serena Nelson, Shamina M. Rangwala, Shannon Mullican, Jose Antonio Chavez